Elligo Health Research vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Clinical Trial Enablement & Patient Recruitment
Elligo Health Research brings clinical trials into healthcare settings by using EHR data for patient identification and providing site infrastructure; enables physicians to conduct trials without becoming dedicated research sites;
About
Elligo Health Research is a clinical research organization (CRO) and technology company founded in 2016 and headquartered in Austin, Texas, that embeds clinical trials within existing healthcare environments rather than requiring dedicated research centers. The company's model enables practicing physicians and health systems to conduct clinical trials for their own patients by providing the infrastructure, personnel, regulatory expertise, and data integration needed to run trials — without requiring those providers to become stand-alone research sites. This "research-in-care" approach significantly broadens the pool of potential trial sites and patients.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Elligo Health Research vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.